Although the UK government's newly-unveiled deal with the life sciences sector holds huge promise, its ambitions will not be realized if appropriate access to de-identified patient level data isn’t extended to commercial organizations for real world evidence studies.
That's the view of Angela McFarlane, market development director for the UK and Ireland for IQVIA, a leading provider of...








